Prev：Cryptotanshinone Attenuated Pathological Cardiac Remodeling In Vivo and In Vitro Experiments(A21010-7)
Next：CTCF, a novel fusion partner of ETO2 in a post-transplant relapsed acute myeloid leukemia patient(A23310-)
